{"id":758679,"date":"2023-05-15T07:06:15","date_gmt":"2023-05-15T11:06:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/"},"modified":"2023-05-15T07:06:15","modified_gmt":"2023-05-15T11:06:15","slug":"first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/","title":{"rendered":"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOCA RATON, Fla., May  15, 2023  (GLOBE NEWSWIRE) &#8212; First Wave BioPharma, Inc. (NASDAQ: FWBI) (\u201cFirst Wave BioPharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for\u202fgastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of First Wave BioPharma, will present at the 2023 BIO International Conference on Tuesday, June 6 11:45 AM in Room 104A. The conference is taking place June 5-8 in the Boston Convention &amp; Exhibition Center in Boston, Massachusetts.<\/p>\n<p>Details of the event are as follows:<\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Event:<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">2023 BIO International Conference<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Date:<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Tuesday, June 6, 2023<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Time:<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">11:45 a.m. ET<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Location:<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Room 104A<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Registration:<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">https:\/\/www.bio.org\/events\/bio-international-convention<\/td>\n<\/tr>\n<\/table>\n<p>Mr. Sapirstein will provide an overview of First Wave BioPharma\u2019s business and clinical development programs and discuss anticipated 2023 milestones.<\/p>\n<p>Additionally, Mr. Sapirstein and members of the First Wave BioPharma management team will be participating in virtual one-on-one partnering meetings with pharmaceutical company executives and registered investors.<\/p>\n<p>\n        <strong>About\u00a0First Wave BioPharma, Inc.<\/strong><br \/>\n        <br \/>First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies \u2013 the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn\u2019s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7s2UkB_xCiY5vPwb3jVjv2iJjI-OqulcWjSin8pKVEI3nmiuoaF1atgwjVZgYFuJZ9niM4CclmEimwCMnGg9P0L2XxcigV-lzsxwnXXi38maUHt8LD_QZfJW57xqfl4dI3cepFxZuL3kZk3pq4UasvRCtLQGIWavkQGPlHaBLRwVGXeVRQ2t_h7LVm282DutB_aUv5Mm_A97OX5bFmrNh59ovGI2zn_2-YB_cWKuT4xrQUtkTRY9OSOo56Jv_Y4y1NqjFj5goDKQ5MqfydZdRg==\" rel=\"nofollow noopener\" target=\"_blank\">www.firstwavebio.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company\u2019s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to maintain compliance with Nasdaq\u2019s continued listing criteria and the effect of a delisting from Nasdaq on the market for the Company\u2019s securities; the size of the potential markets for the Company\u2019s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company\u2019s business, operating results and financial prospects; and the Company\u2019s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company\u2019s financial results are contained in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2022 under the heading \u201cRisk Factors,\u201d as well as the Company\u2019s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.<\/em>\n      <\/p>\n<p>\n        <strong>For more information:<\/strong><br \/>\n        <br \/>First Wave BioPharma, Inc.<br \/>777 Yamato Road, Suite 502<br \/>Boca Raton, FL 33431<br \/>Phone: (561) 589-7020<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wk_rkXK1c5vz033H45NAP3gEXAFHQ7b-8oB3hGWlFsD5-GEj9s4ZoP0iQ1YNYdP8tbk5Sv0Mrbm-h4PpU9z7YAScgdxgfeWQYJkyH7Zw9SU=\" rel=\"nofollow noopener\" target=\"_blank\">info@firstwavebio.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xHqAdudI6xYWWd-7ZROZHrdA_1rPHVy4CnS7K84KYrJ3iA915POAevOwwQ2Y7Turh8VeV1BOUk809u34p36wm22eWrKgcotzdd1qYp2tRnl0bK5rSv9QQIGRYR0Nj6X-\" rel=\"nofollow noopener\" target=\"_blank\">partnering@firstwavebio.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2YwOGYyMDktZWQ2Ny00Y2Q1LTg3MWYtMTZhZDQ1NWFlNmFiLTEwOTM3Nzg=\/tiny\/First-Wave-BioPharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) &#8212; First Wave BioPharma, Inc. (NASDAQ: FWBI) (\u201cFirst Wave BioPharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for\u202fgastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of First Wave BioPharma, will present at the 2023 BIO International Conference on Tuesday, June 6 11:45 AM in Room 104A. The conference is taking place June 5-8 in the Boston Convention &amp; Exhibition Center in Boston, Massachusetts. Details of the event are as follows: Event: 2023 BIO International Conference Date: Tuesday, June 6, 2023 Time: 11:45 a.m. ET Location: Room 104A Registration: https:\/\/www.bio.org\/events\/bio-international-convention Mr. Sapirstein will provide an overview of First Wave BioPharma\u2019s business and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758679","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) &#8212; First Wave BioPharma, Inc. (NASDAQ: FWBI) (\u201cFirst Wave BioPharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for\u202fgastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of First Wave BioPharma, will present at the 2023 BIO International Conference on Tuesday, June 6 11:45 AM in Room 104A. The conference is taking place June 5-8 in the Boston Convention &amp; Exhibition Center in Boston, Massachusetts. Details of the event are as follows: Event: 2023 BIO International Conference Date: Tuesday, June 6, 2023 Time: 11:45 a.m. ET Location: Room 104A Registration: https:\/\/www.bio.org\/events\/bio-international-convention Mr. Sapirstein will provide an overview of First Wave BioPharma\u2019s business and &hellip; Continue reading &quot;First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-15T11:06:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference\",\"datePublished\":\"2023-05-15T11:06:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/\"},\"wordCount\":657,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/\",\"name\":\"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=\",\"datePublished\":\"2023-05-15T11:06:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/","og_locale":"en_US","og_type":"article","og_title":"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference - Market Newsdesk","og_description":"BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) &#8212; First Wave BioPharma, Inc. (NASDAQ: FWBI) (\u201cFirst Wave BioPharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for\u202fgastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of First Wave BioPharma, will present at the 2023 BIO International Conference on Tuesday, June 6 11:45 AM in Room 104A. The conference is taking place June 5-8 in the Boston Convention &amp; Exhibition Center in Boston, Massachusetts. Details of the event are as follows: Event: 2023 BIO International Conference Date: Tuesday, June 6, 2023 Time: 11:45 a.m. ET Location: Room 104A Registration: https:\/\/www.bio.org\/events\/bio-international-convention Mr. Sapirstein will provide an overview of First Wave BioPharma\u2019s business and &hellip; Continue reading \"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-15T11:06:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference","datePublished":"2023-05-15T11:06:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/"},"wordCount":657,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/","name":"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=","datePublished":"2023-05-15T11:06:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNjc3MiM1NTg3NDU2IzIwODIyMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-wave-biopharma-ceo-james-sapirstein-to-present-at-2023-bio-international-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758679"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758679\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}